Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 505 to 509 of 509 entries
Sorted by: Best Match Show Resources per page
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.

Circulation research

Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ.
PMID: 34110908
Circ Res. 2021 Jun 11;128(12):1973-1987. doi: 10.1161/CIRCRESAHA.121.318259. Epub 2021 Jun 10.

Novel targeted cancer therapies have revolutionized oncology therapies, but these treatments can have cardiovascular complications, which include heterogeneous cardiac, metabolic, and vascular sequelae. Vascular side effects have emerged as important considerations in both cancer patients undergoing active treatment and...

Cite
Fleming MR, Xiao L, Jackson KD, et al. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circ Res. 2021;128(12):1973-1987doi: 10.1161/CIRCRESAHA.121.318259.
Fleming, M. R., Xiao, L., Jackson, K. D., Beckman, J. A., Barac, A., & Moslehi, J. J. (2021). Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circulation research, 128(12), 1973-1987. https://doi.org/10.1161/CIRCRESAHA.121.318259
Fleming, Matthew R, et al. "Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors." Circulation research vol. 128,12 (2021): 1973-1987. doi: https://doi.org/10.1161/CIRCRESAHA.121.318259
Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circ Res. 2021 Jun 11;128(12):1973-1987. doi: 10.1161/CIRCRESAHA.121.318259. Epub 2021 Jun 10. PMID: 34110908.
Copy Download .nbib Format: NLM
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.

Cell reports. Medicine

Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW, Stein J, Tsai HL, Wang H, Belcaid Z, Murray J, Balan A, Ferreira L, Ross-Macdonald P, Wind-Rotolo M, Baras AS, Taube J, Karchin R, Scharpf RB, Grasso C, Ribas A, Pardoll DM, Topalian SL, Velculescu VE.
PMID: 33294860
Cell Rep Med. 2020 Nov 17;1(8):100139. doi: 10.1016/j.xcrm.2020.100139. eCollection 2020 Nov 17.

In this study, we incorporate analyses of genome-wide sequence and structural alterations with pre- and on-therapy transcriptomic and T cell repertoire features in immunotherapy-naive melanoma patients treated with immune checkpoint blockade. Although tumor mutation burden is associated with improved...

Cite
Anagnostou V, Bruhm DC, Niknafs N, et al. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Rep Med. 2020;1(8):100139doi: 10.1016/j.xcrm.2020.100139.
Anagnostou, V., Bruhm, D. C., Niknafs, N., White, J. R., Shao, X. M., Sidhom, J. W., Stein, J., Tsai, H. L., Wang, H., Belcaid, Z., Murray, J., Balan, A., Ferreira, L., Ross-Macdonald, P., Wind-Rotolo, M., Baras, A. S., Taube, J., Karchin, R., Scharpf, R. B., Grasso, C., Ribas, A., Pardoll, D. M., Topalian, S. L., & Velculescu, V. E. (2020). Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell reports. Medicine, 1(8), 100139. https://doi.org/10.1016/j.xcrm.2020.100139
Anagnostou, Valsamo, et al. "Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma." Cell reports. Medicine vol. 1,8 (2020): 100139. doi: https://doi.org/10.1016/j.xcrm.2020.100139
Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW, Stein J, Tsai HL, Wang H, Belcaid Z, Murray J, Balan A, Ferreira L, Ross-Macdonald P, Wind-Rotolo M, Baras AS, Taube J, Karchin R, Scharpf RB, Grasso C, Ribas A, Pardoll DM, Topalian SL, Velculescu VE. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Rep Med. 2020 Nov 17;1(8):100139. doi: 10.1016/j.xcrm.2020.100139. eCollection 2020 Nov 17. PMID: 33294860; PMCID: PMC7691441.
Copy Download .nbib Format: NLM
CLIP and Massively Parallel Functional Analysis of CELF6 Reveal a Role in Destabilizing Synaptic Gene mRNAs through Interaction with 3' UTR Elements.

Cell reports

Rieger MA, King DM, Crosby H, Liu Y, Cohen BA, Dougherty JD.
PMID: 33357440
Cell Rep. 2020 Dec 22;33(12):108531. doi: 10.1016/j.celrep.2020.108531.

CELF6 is a CELF-RNA-binding protein, and thus part of a protein family with roles in human disease; however, its mRNA targets in the brain are largely unknown. Using cross-linking immunoprecipitation and sequencing (CLIP-seq), we define its CNS targets, which...

Cite
Rieger MA, King DM, Crosby H, et al. CLIP and Massively Parallel Functional Analysis of CELF6 Reveal a Role in Destabilizing Synaptic Gene mRNAs through Interaction with 3' UTR Elements. Cell Rep. 2020;33(12):108531doi: 10.1016/j.celrep.2020.108531.
Rieger, M. A., King, D. M., Crosby, H., Liu, Y., Cohen, B. A., & Dougherty, J. D. (2020). CLIP and Massively Parallel Functional Analysis of CELF6 Reveal a Role in Destabilizing Synaptic Gene mRNAs through Interaction with 3' UTR Elements. Cell reports, 33(12), 108531. https://doi.org/10.1016/j.celrep.2020.108531
Rieger, Michael A, et al. "CLIP and Massively Parallel Functional Analysis of CELF6 Reveal a Role in Destabilizing Synaptic Gene mRNAs through Interaction with 3' UTR Elements." Cell reports vol. 33,12 (2020): 108531. doi: https://doi.org/10.1016/j.celrep.2020.108531
Rieger MA, King DM, Crosby H, Liu Y, Cohen BA, Dougherty JD. CLIP and Massively Parallel Functional Analysis of CELF6 Reveal a Role in Destabilizing Synaptic Gene mRNAs through Interaction with 3' UTR Elements. Cell Rep. 2020 Dec 22;33(12):108531. doi: 10.1016/j.celrep.2020.108531. PMID: 33357440; PMCID: PMC7780154.
Copy Download .nbib Format: NLM
Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels.

Science advances

Kurth I, Yamaguchi N, Andreu-Agullo C, Tian HS, Sridhar S, Takeda S, Gonsalves FC, Loo JM, Barlas A, Manova-Todorova K, Busby R, Bendell JC, Strauss J, Fakih M, McRee AJ, Hendifar AE, Rosen LS, Cercek A, Wasserman R, Szarek M, Spector SL, Raza S, Tavazoie MF, Tavazoie SF.
PMID: 34613776
Sci Adv. 2021 Oct 08;7(41):eabi7511. doi: 10.1126/sciadv.abi7511. Epub 2021 Oct 06.

[Figure: see text].

Cite
Kurth I, Yamaguchi N, Andreu-Agullo C, et al. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Sci Adv. 2021;7(41):eabi7511doi: 10.1126/sciadv.abi7511.
Kurth, I., Yamaguchi, N., Andreu-Agullo, C., Tian, H. S., Sridhar, S., Takeda, S., Gonsalves, F. C., Loo, J. M., Barlas, A., Manova-Todorova, K., Busby, R., Bendell, J. C., Strauss, J., Fakih, M., McRee, A. J., Hendifar, A. E., Rosen, L. S., Cercek, A., Wasserman, R., Szarek, M., Spector, S. L., Raza, S., Tavazoie, M. F., & Tavazoie, S. F. (2021). Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Science advances, 7(41), eabi7511. https://doi.org/10.1126/sciadv.abi7511
Kurth, Isabel, et al. "Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels." Science advances vol. 7,41 (2021): eabi7511. doi: https://doi.org/10.1126/sciadv.abi7511
Kurth I, Yamaguchi N, Andreu-Agullo C, Tian HS, Sridhar S, Takeda S, Gonsalves FC, Loo JM, Barlas A, Manova-Todorova K, Busby R, Bendell JC, Strauss J, Fakih M, McRee AJ, Hendifar AE, Rosen LS, Cercek A, Wasserman R, Szarek M, Spector SL, Raza S, Tavazoie MF, Tavazoie SF. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Sci Adv. 2021 Oct 08;7(41):eabi7511. doi: 10.1126/sciadv.abi7511. Epub 2021 Oct 06. PMID: 34613776; PMCID: PMC8494442.
Copy Download .nbib Format: NLM
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.

The Lancet. Respiratory medicine

Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, Staudinger H, Horowitz JE, Baras A, Ferreira MA, Ruddy MK, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H.
PMID: 34302758
Lancet Respir Med. 2021 Nov;9(11):1288-1298. doi: 10.1016/S2213-2600(21)00167-3. Epub 2021 Jul 21.

BACKGROUND: Genetic data implicate IL-33 in asthma susceptibility. Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD). In this study we first aimed to test the hypothesis that genetic...

Cite
Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021;9(11):1288-1298doi: 10.1016/S2213-2600(21)00167-3.
Rabe, K. F., Celli, B. R., Wechsler, M. E., Abdulai, R. M., Luo, X., Boomsma, M. M., Staudinger, H., Horowitz, J. E., Baras, A., Ferreira, M. A., Ruddy, M. K., Nivens, M. C., Amin, N., Weinreich, D. M., Yancopoulos, G. D., & Goulaouic, H. (2021). Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. The Lancet. Respiratory medicine, 9(11), 1288-1298. https://doi.org/10.1016/S2213-2600(21)00167-3
Rabe, Klaus F, et al. "Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial." The Lancet. Respiratory medicine vol. 9,11 (2021): 1288-1298. doi: https://doi.org/10.1016/S2213-2600(21)00167-3
Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, Staudinger H, Horowitz JE, Baras A, Ferreira MA, Ruddy MK, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288-1298. doi: 10.1016/S2213-2600(21)00167-3. Epub 2021 Jul 21. PMID: 34302758.
Copy Download .nbib Format: NLM
Showing 505 to 509 of 509 entries